Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 4, 1999, for EG&G, Inc. (Note: The company later became REVVITY, Inc.). The registrant operates through five Strategic Business Units (SBUs): Life Sciences, Optoelectronics, Instruments, Engineered Products, and Technical Services. The financial statements are unaudited and reflect the company's transformation efforts, including recent acquisitions and ongoing restructuring.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Total Sales | $357.5 million | $355.9 million |
| Operating Income | $25.8 million | $54.9 million |
| Net Income | $14.1 million | $34.5 million |
| Diluted EPS | $0.31 | $0.75 |
| Cash from Operations | $10.2 million | $10.0 million |
| Cash and Equivalents | $106.3 million | $102.9 million |
| Short-Term Debt | $184.1 million | $157.9 million |
| Long-Term Debt | $117.3 million | $129.8 million |
Operating Margins: Operating income margin for Q1 1999 was 7.2% of sales, compared to 15.4% in Q1 1998 (which included significant one-time gains).
Material Changes vs. Prior Period
- Revenue Stability: Total sales increased slightly by $1.6 million (0.4%). This masks a 16% decline in the Technical Services segment due to the expiration of a major NASA contract ($40.2 million in Q1 1998), offset by a 58% surge in Optoelectronics sales driven by the Lumen Technologies acquisition.
- Profitability Decline: Net income dropped 59% year-over-year. The Q1 1998 results were inflated by $67.5 million in gains from business dispositions (Rotron and Sealol) and were burdened by $31.4 million in restructuring charges. Excluding these non-recurring items, Q1 1999 operating income actually increased by approximately 37% compared to the adjusted Q1 1998 figure.
- Segment Performance:
- Optoelectronics: Turned a $7.3 million loss in Q1 1998 into a $7.8 million profit in Q1 1999, largely due to Lumen.
- Technical Services: Sales fell $22 million, but operating profit rose 16% to $6.6 million due to cost controls and new government contracts.
- Life Sciences: Sales up 12% and operating profit up 533% (excluding prior year restructuring charges).
- Debt Levels: Short-term debt increased by $26.2 million, primarily due to commercial paper borrowings used to finance the Lumen acquisition and working capital needs.
Guidance, Outlook, and Risks
- Acquisitions: The company announced an agreement to acquire Perkin-Elmer's Analytical Instruments Division for approximately $425 million, expected to close in Q2 1999. This includes assuming a $65 million pension liability.
- Strategic Review: Management is exploring strategic alternatives for the Technical Services segment, having engaged Goldman Sachs to conduct a review.
- Restructuring: The company expects to incur approximately $28.5 million in cash outlays for restructuring plans throughout the remainder of 1999. Full-year pre-tax savings from these plans are anticipated to be $24 million.
- Year 2000 (Y2K) Readiness: The company is in the remediation execution phase. Estimated costs to address Y2K through April 4, 1999, were $6.7 million, with an additional $3.4 million expected in 1999. Management believes there is no single worst-case scenario that would materially affect operations short of a national infrastructure catastrophe.
- Liquidity: The company has a $250 million credit facility expiring in March 2000 and a $100 million facility expiring in March 2002. It plans to fund the Perkin-Elmer acquisition using cash, credit facilities, and other financing.
Investor Verification Checklist
- Adjusted Earnings: Verify the "normalized" operating income growth of 37% by excluding the $67.5 million gain on dispositions and $31.4 million restructuring charge from the Q1 1998 results.
- Perkin-Elmer Financing: Confirm the funding sources for the $425 million acquisition and the impact of the $65 million pension liability on future cash flows.
- Technical Services Strategy: Monitor the outcome of the strategic review for the Technical Services segment, which saw a significant revenue drop due to the lost NASA contract.
- Restructuring Execution: Track the $28.5 million in expected remaining cash outlays for restructuring and the realization of the projected $24 million in annual savings.
- Y2K Contingencies: Review the status of the "high risk" operational units within the Instruments and Technical Services SBUs regarding Y2K compliance.